NasdaqGS:BEAMBiotechs
Beam Therapeutics Taps US$500m Non Dilutive Debt To Back Risto Cel
Beam Therapeutics entered a long term, non dilutive financing agreement with Sixth Street to support the potential launch of its sickle cell gene therapy.
The deal provides access to up to $500 million in capital tied to Beam’s commercial plans for this program.
The agreement focuses on funding potential product launch and commercialization activities rather than issuing new equity.
For investors watching NasdaqGS:BEAM, this financing move comes with the stock trading around $28.33 and a...